Celecoxib-loaded poly(D,L-lactide-co-glycolide) nanoparticles prepared using a novel and controllable combination of diffusion and emulsification steps as part of the salting-out procedure.
A novel procedure for the manufacture of celecoxib-loaded poly(D,L-lactide-co-glycolide) (PLGA) nanoparticles is described that is based upon combining salting out and emulsion-evaporation steps. An entrapment efficiency, a measure of the actual to theoretical drug content, of 97.3% was achieved, being superior to that achieved when these popular techniques were used separately (emulsion evaporation, 40.1%; salting out, 10.0%). The ratio of a water miscible solvent (acetone) to a non water-miscible solvent (dichloromethane) was shown to be the primary determinants of size and drug loading. Once optimized, using an organic phase of 3 : 1 acetone : dichloromethane vol : vol ratio, further control on particle parameters could be exerted using modification of acetone diffusion by alterations in MgCl2 x 6H2O concentration. This step was shown to have a small effect on both the mean nanoparticle size and entrapment efficiency, but found to reduce the polydispersity considerably. Diffusion control using a 45% w/v MgCl2 x 6H2O solution produced nanoparticles with a mean size of 151.4 nm, a polydispersity index of 0.023 and 98.1% entrapment efficiency. Electron microscopy showed the particles to be smooth and spherical. Sheer homogenization during the emulsification step was shown to be not as effective as sonication, with the latter technique able to produce nanoparticles after 1 min of application. Drug release studies across a semi-permeable membrane demonstrated a reduction in the burst effect as the ratio of acetone in the organic phase was increased. Calorimetry studies suggested that celecoxib existed in the nanoparticle as a molecular dispersion, with additional evidence for a strong interaction between the PLGA and the absorbed poly(vinyl alcohol) stabilizer. Formation of a strong interaction between celecoxib and PLGA, together with the formation of a radial drug gradient give a release profile that does not possess the prevalent burst effect seen with other nanoparticulate drug-loaded systems.
McCarron
Paul A
PA
School of Pharmacy, Queens University Belfast, Medical Biology Centre, Belfast, UK. p.mccarron@qub.ac.uk
Donnelly
Ryan F
RF
Marouf
Waleed
W
D000096:Acetone / Q000737:chemistry; D001672:Biocompatible Materials / Q000737:chemistry; D002152:Calorimetry, Differential Scanning / Q000379:methods; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors; D003692:Delayed-Action Preparations / Q000737:chemistry; D004058:Diffusion; D004339:Drug Compounding / Q000379:methods; D019344:Lactic Acid / Q000737:chemistry*; D015636:Magnesium Chloride / Q000737:chemistry; D008752:Methylene Chloride / Q000737:chemistry; D008855:Microscopy, Electron, Scanning / Q000379:methods; D053758:Nanoparticles / Q000737:chemistry*; D010316:Particle Size; D011100:Polyglycolic Acid / Q000737:chemistry*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000737:chemistry*; D011720:Pyrazoles; D012997:Solvents / Q000737:chemistry; D013010:Sonication; D013449:Sulfonamides; D013499:Surface Properties; D014783:Viscosity
D001672:Biocompatible Materials; D016861:Cyclooxygenase Inhibitors; D003692:Delayed-Action Preparations; D011108:Polymers; D011720:Pyrazoles; D012997:Solvents; D013449:Sulfonamides; D015636:Magnesium Chloride; D000096:Acetone; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D008752:Methylene Chloride; D000068579:Celecoxib